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Every organ system of the human body is alive with micro-organisms, 
i.e. the microbiome. This constitutes a group of microbial organisms 
that inhabit every system of the body and consists of microbial 
species and their associated genomes living on, and in, humans. 
Although there are multiple distinct microbiomes found at distinct 
sites and there is individual variation, the composition at any site 
is broadly similar in health. The microbiome interacts extensively 
with the host and outnumbers human gene content 100-fold. Among 
its functions are to afford mucosal protection to allergens and 
infecting organisms,[1] which also contribute to metabolic capacity 
and drive immune development. Disturbances in the microbiome are 
associated with many inflammatory and autoimmune diseases. 
The human body is exposed to a multitude of microbes and 
infectious organisms throughout life. Many of these organisms colonise 
the skin, gastrointestinal tract (GIT) and airway. We now recognise that 
this colonisation includes the lower airway, previously thought to be 
sterile. These colonising organisms play an important role in disease 
prevention, including an array of chronic inflammatory conditions that 
are unrelated to infectious diseases. However, new evidence of immune 
dysregulation suggests that early colonisation, especially of the GIT 
and airway, by pathogenic micro-organisms, has deleterious effects 
that may contribute to the potential to induce chronic inflammation in 
young children, which may only express itself in adult life.
Atopic individuals, who have an underlying allergic condition, 
have frequent disease exacerbations, mostly produced by infectious 
organisms, viruses and bacteria, depending on the specific condition.
A new concept is emerging in the aetiology and therefore the 
prevention of many chronic diseases (including allergy, metabolic 
syndrome and other chronic inflammatory conditions) through a 
new understanding of the importance of the interaction of the body 
with the human microbiome early in life.
In the aetiology of allergic conditions it is now well known that allergic 
predisposition is conveyed on a genetically at-risk young child by the 
interaction of perturbation of the child’s gastrointestinal microbiome, 
lack of allergen exposure early in life (and especially foods in the young 
gut) and absence of immune-modulatory support.[2] This model is well 
developed in the context of food allergy and atopic dermatitis, but there 
is a paucity of data on these associations with airway allergic diseases.[3] 
Therefore, although it seems likely that an allergic diathesis develop-
ing in a young child will ultimately lead to allergic rhinitis and atopic 
asthma through the concept of the allergic march, there must be 
other or additional mechanisms to explain the onset of these airway 
inflammatory diseases.[3] The local airway microbiome is important in 
this regard and changes here may well spell the onset of disease.
Since the description of the hygiene hypothesis by Strachan[4] in 
1989, there has been significant work in this domain. While the original 
hypothesis derived from his study showed that a child’s risk of develop-
ing allergic rhinitis (hay fever) was inversely related to the number of 
older siblings in the family, and the suggestion that microbial exposure 
early in life protects against allergic rhinitis, eczema and asthma, the 
term has evolved. More appropriate terms may be the microbial hypoth-
esis (avoiding an overemphasis on cleanliness), old-friends hypothesis 
(implying that microbes that were beneficial for immune system devel-
opment have been eliminated or replaced) and probably most correctly 
the biodiversity hypothesis or biome depletion.[5] The real problem is that 
many chronic inflammatory diseases, including allergy, are associated with 
both a replacement and a depletion of the normal microbiome (Fig. 1). 
The normal microbiome (both diversity and content) is important 
in its interaction with pattern recognition receptors on epithelial 
cells, which, in turn, regulate the relationship between pro- and anti-
inflammatory cytokines, chemokines and mediators.[6] 
Finally, once a chronic inflammatory airway disease has developed, 
there is an ongoing and important relationship with the local micro-
biome in disease exacerbations.
Organisms are more numerous in the upper-respiratory than the lower-
respiratory tract. Healthy subjects demonstrate a diverse microbiome, 
which often includes potential pathogens such as Pseudomonas aerugi­
nosa, Staphylococcus aureus and various streptococcal species. When 
infection ensues, the microbiome is disrupted, causing community 
collapse with loss of diversity and overgrowth of pathogenic species.[1]
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Despite the seemingly unrelated association 
between the early gut and the respiratory 
tract, there is a certain cross-talk between 
the microbiome in the GIT and the airway 
through a gut-respiratory tract axis so that 
changes in the GIT microbiome create phys-
iological changes in the airway (Fig. 2).[7]
Chronic airway 
disease and bacterial 
colonisation of the 
respiratory tract 
There is now clear evidence that colonisation 
of the nasopharynx in the first month of life 
by Streptococcus pneumoniae, Haemophilus 
influenzae and Moraxella catarrhalis is posi-
tively associated with recurrent wheeze, fol-
lowed by asthma by 5 years of age.[8] It may 
be true that the origin of allergic rhinitis has 
a similar link.
The bacterial 
microbiome in chronic 
rhinosinusitis
Once a chronic allergic and inflammatory 
diathesis is established in the upper-respira -
tory tract, both the nose and sinuses become 
inflamed and symptoms ensue. These sites 
also harbour a microbiome that is intimately 
involved in the allergic disease process, both 
chronically and during disease exacerba-
tions. It is difficult to call this the normal 
microbiome, as the airway is already ill. It is 
a resident microbiome. Conventional culture 
of airway secretions may reveal the usual 
bacterial species, including S. aureus (and 
coagulase-negative staphylococci), strep-
tococci spp., H. influenzae and anaerobes 
(Prevotella and Peptostreptococcus). How-
ever, there is significant variability between 
studies.[6]
New techinques employing the 16S rRNA 
gene wide sequencing have uncovered a pop-
ulation of bacteria that are not found on con-
ventional culture. However, different studies 
reveal different organisms. Stephenson et al.[9] 
identified anaerobic bacteria (Diaphoro bacter, 
Peptoniphilus) in 78% and 72% of chronic 
rhinosinusitis cases, respectively, but not in 
controls, and S. aureus was found in half of 
the chronic rhinosinusitis cases, while it was 
detected in all controls.[9]
Another study, however, revealed Pseudo­
monas, Citrobacter, Haemophilus propioni­
bacterium, Staphylococcus and Strep tococcus 
as the resident microbiomes.[10]
There are a number of confounders in these 
studies, however, which may in part explain dif-
ferent organism identification. These confound-
ers include antibiotic use, steroid use, sampling 
method, exacerbations, variability in constitu-
tive epithelial host-defense molecule secretion 
based on the region of the nose and sinuses sam-
pled, and lastly the associated comorbidities.[11]
It seems that an explanation for these study 
differences lies therein that the microbiome 
is individual specific, which may be one of 
the explanations for difficulty in therapeutic 
attempts.
The fungal and viral 
microbiome in chronic 
rhinosinusitis
Just as there is a resident bacterial micro-
biome in chronic rhino sinusitis, there is 
also a fungal microbiome. Species, including 
Candida, Aspergillus and Mucor, differ in stud-
ies and may even be found in asymptomatic 
control subjects.[12] 
Employing multiplex polymerase chain 
reaction for respiratory viruses, viral nucleic 
acid sequences have been found in 64% 
of sinus scrapings and 50% of nasal lavage 
samples in a chronic rhinosinusitis group of 
patients.[13] These were significantly higher 
than in controls (30% and 14% in scraping 
and lavage, respectively) and rhinovirus was 
the most frequently detected virus.[13]
Biofilm
Many of the early microbiological studies of 
bacteria, including their discovery and char-
acterisation, were performed with planktonic 
bacteria, which are characterised as individual 
free-living (free-swimming) bacteria.[14] Even 
currently, standard laboratory culture tech-
niques use planktonic bacteria that grow rapidly 
in nutrient-rich media. However, with the use 
of modern molecular techniques, it has become 
apparent that there are large populations of 
organisms in the human host that cannot be 
cultured by these standard techniques, as these 
organisms have adapted to a different type of 
growth.[14] Most bacteria exist in complex, tight-
knit colonies or communities often strongly 
adherent to surfaces; it has been reported that 
<1% of bacteria exist in planktonic form and 
that ≥99% of bacteria live in these types of 
biofilms.[14-16] 
Biofilms comprise highly structured com-
munities of bacteria that exist within an extra-
cellular matrix that consists of polysaccha-
rides, nucleic acids and proteins, the so-called 
extracellular polymeric substances.[15,16] 
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The formation of mature biofilms occurs in stages, proceeding through 
a number of well-characterised steps that are regulated by the bacterial 
quorum sensing system.[15-17] The latter involves communication between 
the bacterial cells through the release of small protein pheromones 
that control bacterial gene expression and therefore co-ordinate their 
behaviour.[18] Many bacteria, particularly those associated with chronic 
infection, including S. pneumoniae, P. aeruginosa, H. influenzae, 
S. aureus and Escherichia coli, are known to produce biofilm.[17-19] 
The characteristics of the micro-organisms in biofilm differ greatly 
from those of planktonic bacteria.[14] Bacteria within biofilms undergo 
changes in their expression of virulence factors and/or surface mole-
cules, their utilisation of nutrients, and their cell turnover rates.[19] 
Also, very importantly, there is an increase in antibiotic resistance in 
bacterial biofilms. Bacterial biofilms may be up to 1 000 times more 
resistant to antibiotics than planktonic bacteria, which are geneti-
cally identical.[15] The mechanism of antibiotic resistance appears to 
be multifactorial, including factors such as impeded pene tration of 
antibiotics into the biofilm.[19] However, one important mechanism 
relates to a slow metabolic rate and turnover of bacteria deep within the 
nutrient-depleted zone of the biofilm so that these micro-organisms 
are less susceptible to antibiotics that target cell wall synthesis, which 
are much more active against bacteria that turn over rapidly.[15,19] 
Biofilm bacteria are also more resistant to host defences, which 
frequently results in both persistence of the biofilms and ongoing 
surrounding inflammation.[15] We are beginning to understand the 
important role of bacterial biofilms in a number of infections, including 
chronic lower-airway infections, such as cystic fibrosis, bronchiectasis 
and chronic obstructive pulmonary disease; device-related infections; 
and various otolaryngology conditions, including chronic rhinosinusitis, 
among many others, which are extremely difficult to treat.[14-16,19] 
Current status of probiotic use in 
chronic airway disease management
It is theoretically possible that restoration of the microbiome could 
increase resistance to infection and decrease allergic responses. In 
this regard, numerous studies have been performed, most relying on 
the link between the gut and the respiratory tract, the so-called gut-
respiratory tract axis. Unfortunately, these studies have generally been 
small, have used multiple different probiotics in different doses, and 
have utilised different administration schedules. A recent systematic 
review of the literature showed seven randomised, placebo-controlled 
trials involving the use of different probiotics. Two studies (N=170) 
specifically evaluated quality of life (QOL), frequency of symptoms, 
and level of bother, and found a statistically significant improvement. 
Although there was a decrease in episodes of rhinitis per year, there 
was no change in blood or immunological parameters and no effect 
on time free from rhinitis episodes or mean duration of episodes.[20]
Similarly, a more recent systematic review and meta-analysis 
involving MEDLINE, Embase and Cochrane Library databases, found 
21 double-blind randomised controlled trials and two rando mised 
crossover studies (N=1 919) involving multiple pro biotics, populations 
and outcomes.[21] Seventeen of these showed significant clinical benefit 
in one or more outcome measures; however, six showed no benefit. 
Among the trials eligible for meta-analysis, the rhinitis QOL score 
improved significantly, but there was no effect on total symptom 
score or IgE. Their conclusion was ‘that probiotics may be beneficial 
in improving symptoms and QOL in patients with allergic rhinitis; 
however, current evidence remains limited due to study heterogeneity 
and variable outcome measures. Additional high-quality studies are 
needed to establish appropriate recommendations.’[21]
Some unanswered questions therefore arise from these studies and 
this replacement concept. These include what mixture of probiotics is 
best, what the timing of administration should be, and where best the 
probiotics should be sited (the gut or directly into the nose or sinuses). 
As there is good evidence for efficacy (microbial burden change 
and inflammatory response modification) in mouse models for topical 
application of probiotics, this model needs urgent human studies.
Conclusion
The microbiome in the upper-respiratory tract is a dynamic organ. Dysbio-
sis is easy to produce in many disease states, and with the use of many drug 
therapies, including antibiotics and nasal steroids, the upper-respiratory 
tract is susceptible to significant pertubations and exacerbations.
As studies demonstrating that restoring the microbiome in the 
nose and sinuses are currently not effective, it seems prudent to try to 
protect the resident or normal microbiome at all costs.
Both the microbiome of the young gut and that of the upper-
respiratory tract early in life are vital to disease prevention, as when 
dysbiosis and depletion occur, chronic inflammatory disease ensues.
As a society, and as a scientific community, we need to look carefully 
at the many strategies we currently allow that interfere with the health 
of this important human asset, the normal microbiome. Once gone, it 
is almost certainly too late to retrieve it.
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